The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children

Knights, 2013, Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome, Gut, 62, 1505, 10.1136/gutjnl-2012-303954 Levine, 2014, Diagnosis of inflammatory bowel disease in children and adolescents: the Revised Porto Criteria, J Pediatr Gastroenterol Nutr., 58, 795, 10.1097/MPG.0000000000000239 Mowat, 2011, Guidelines for the management of inflammatory bowel disease in adults, Gut, 60, 571, 10.1136/gut.2010.224154 Markowitz, 2000, A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease, Gastroenterology, 119, 895, 10.1053/gast.2000.18144 Bradley, 2012, Pediatric ulcerative colitis: current treatment approaches including role of infliximab, Biologics, 6, 125 Parashette, 2010, Infliximab therapy in pediatric Crohn's disease: a review, Clin Exp Gastroenterol, 3, 57 Plevy, 1997, A role for TNF alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease, J Immunol, 159, 6276, 10.4049/jimmunol.159.12.6276 Ricciardelli, 2008, Anti tumour necrosis-α therapy increases the number of FOX3+ regulatory T cell in children affected by Crohn's disease, Immunology, 125, 178, 10.1111/j.1365-2567.2008.02839.x Sandborn, 2008, Current directions in IBD therapy: what goals are feasible with biological modifiers?, Gastroenterology, 135, 1442, 10.1053/j.gastro.2008.09.053 Borrelli, 2004, Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease, Dig Liver Dis, 36, 342, 10.1016/j.dld.2003.12.014 Oussalah, 2010, Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review, Curr Drug Targets, 11, 156, 10.2174/138945010790309939 Weiwad, 2006, Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins, Biochemistry, 45, 15776, 10.1021/bi061616p Massey, 2008, Use of sirolimus (rapamycin) to treat refractory Crohn's disease, Gut, 57, 1294, 10.1136/gut.2008.157297 Borrelli, 2006, Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial, Clin Gastroenterol Hepatol, 4, 744, 10.1016/j.cgh.2006.03.010 Turner, 2012, Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response, Gastroenterology, 138, 2282, 10.1053/j.gastro.2010.02.047 Hanauer, 1998, Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group, Gastroenterology, 115, 525, 10.1016/S0016-5085(98)70131-3 D'Haens, 1998, Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum, Gastroenterology, 114, 262, 10.1016/S0016-5085(98)70476-7 Yong, 2008, Use of sirolimus in IPEX and IPEX-like children, J Clin Immunol, 28, 581, 10.1007/s10875-008-9196-1 Tsang, 2007, Targeting mammalian target of rapamycin (mTOR) for health and diseases, Drug Discov Today, 12, 112, 10.1016/j.drudis.2006.12.008 Abraham, 1996, Immunopharmacology of rapamycin, Annu Rev Immunol, 14, 483, 10.1146/annurev.immunol.14.1.483 Abouelnasr, 2013, Defining the role of sirolimus in the management of graft-versus-host disease: from prophylaxis to treatment, Biol Blood Marrow Transplant, 19, 12, 10.1016/j.bbmt.2012.06.020 Johnson, 2002, Sirolimus (Rapamune) in renal transplantation, Curr Opin Nephrol Hypertens, 11, 603, 10.1097/00041552-200211000-00006 Trotter, 2003, Sirolimus in liver transplantation, Transplant Proc, 35, 1935 Pascual, 2005, Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors, Transplantation, 79, S76, 10.1097/01.TP.0000162434.62591.F3 Farkas, 2006, Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis, Int J Colorectal Dis, 21, 747, 10.1007/s00384-005-0793-7 Rioux, 2007, Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis, Nat Genet, 39, 596, 10.1038/ng2032 Ravikumar, 2004, Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntingdon disease, Nat Genet, 36, 585, 10.1038/ng1362